Neuraxis Inc (NRXS) News

Form S-3 - Registration statement under Securities Act of 1933

NeurAxis Inc. Announces FDA 510(k) Clearance of RED for Testing and Evaluation of Patients with Chronic Constipation

RED has been designed to duplicate test performance of traditional balloon expulsion test (BET) and manual...

Form 8-K - Current report

Form 8-K - Current report

Form 8-K - Current report

NeurAxis Reports Strong Third Quarter 2024 Financial Results Driven by a 40% Increase in Revenues

CARMEL, Ind., Nov. 12, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American:...

NeurAxis to Host Third Quarter 2024 Results and Business Update Call on Tuesday, November 12, 2024

CARMEL, Ind., Nov. 05, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American:...

NeurAxis Receives New FDA 510(K) Clearance for IB-Stim, Expanding its Addressable Market

CARMEL, Ind., Nov. 04, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American:...

NeurAxis Announces Capital Blue Cross Medical Policy Coverage for PENFS, effective October 1st 2024

CARMEL, Ind., Oct. 29, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American:...

NeurAxis Announces New CPT® Category I Code for Percutaneous Electrical Nerve Field Stimulation

CARMEL, Ind., Oct. 22, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American:...

Form 8-K - Current report

NeurAxis to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024

CARMEL, Ind., Sept. 19, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE...

Form 8-K - Current report

NeurAxis Announces Geisinger Health Plan Medical Policy Coverage for PENFS, Effective September 15 2024

CARMEL, Ind., Aug. 27, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American:...

Form 8-K - Current report